Abstract
Interleukin (IL)-4 and IL-13 are two structurally and functionally related cytokines that have overlapping but also distinct biological activities. One of the components of the IL-13 receptor, the α2 chain (IL-13Rα2), has been reported to downregulate the cell responsiveness to IL-13, without affecting IL-4 signaling. Here, we report that TNFα synergizes with either IL-4 or IL-13 in inducing the IL-13Rα2 chain at both the mRNA and protein levels in the HaCaT human keratinocyte cell line. Further studies by 5′RACE identified as yet undescribed exonic sequences of the IL-13Rα2 5′UTR, provided evidence for the expression of alternatively spliced IL-13Rα2 transcripts and defined the transcription start of the IL-13Rα2 gene. A 1.5 kb region upstream of the first exon of the IL-13Rα2 gene displayed basal promoter activity when inserted in a reporter plasmid and transiently transfected in HaCaT cells. This promoter activity was further increased in response to IL-4 and IL-13. Furthermore, by electrophoretic mobility shift assay and site-directed mutagenesis, we showed that the IL-4/IL-13-induced promoter activity depended upon a positively acting STAT6 response element. Finally, TNFα was shown to potentiate IL-4/IL-13-induced IL-13Rα2 promoter activity when the same reporter construct was studied in stably but not in transiently transfected cells. These results suggest that the synergistic effect of TNFα on IL-4/IL-13-induced IL-13Rα2 expression is dependent upon chromatin re-modeling events.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS and Leonard WJ . (1996). J. Biol. Chem., 271, 29265–29270.
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE . (1988). J. Cell Biol., 106, 761–771.
Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N and Ferrara P . (1996). J. Biol. Chem., 271, 16921–16926.
Chen CY, Del Gatto-Konczak F, Wu Z and Karin M . (1998). Science, 280, 1945–1949.
Chiaramonte MG, Donaldson DD, Cheever AW and Wynn TA . (1999). J. Clin. Invest., 104, 777–785.
Daines MO and Hershey GK . (2002). J. Biol. Chem., 277, 10387–10393.
David M, Ford D, Bertoglio J, Maizel AL and Pierre J . (2001). Oncogene, 20, 6660–6668.
Debinski W, Gibo DM, Hulet SW, Connor JR and Gillespie GY . (1999a). Clin. Cancer Res., 5, 985–990.
Debinski W, Gibo DM, Slagle B, Powers SK and Gillespie GY . (1999b). Int. J. Oncol., 15, 481–486.
Debinski W, Obiri NI, Pastan I and Puri RK . (1995). J. Biol. Chem., 270, 16775–16780.
Defrance T, Carayon P, Billian G, Guillemot JC, Minty A, Caput D and Ferrara P . (1994). J. Exp. Med., 179, 135–143.
de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G and de Vries JE . (1993). J. Immunol., 151, 6370–6381.
Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C and Azzarone B . (1998). J. Clin. Invest., 101, 2129–2139.
Feng N, Lugli SM, Schnyder B, Gauchat JF, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr-Adam M, Duschl A, Heim MH, Lutz RA and Moser R . (1998). Lab. Invest., 78, 591–602.
Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, Peat JD, Vazquez N, Pestka S, Donnelly RP and Kotenko SV . (2000). Genes Immun., 1, 442–450.
Gauchat JF, Schlagenhauf E, Feng NP, Moser R, Yamage M, Jeannin P, Alouani S, Elson G, Notarangelo LD, Wells T, Eugster HP and Bonnefoy JY . (1997). Eur. J. Immunol., 27, 971–978.
Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM and Corry DB . (1998). Science, 282, 2261–2263.
Guo J, Apiou F, Mellerin MP, Lebeau B, Jacques Y and Minvielle S . (1997). Genomics, 42, 141–145.
Guo D, Dunbar JD, Yang CH, Pfeffer LM and Donner DB . (1998). J. Immunol., 160, 2742–2750.
Hart PH, Bonder CS, Balogh J, Dickensheets HL, Donnelly RP and Finlay-Jones JJ . (1999). J. Leukoc. Biol., 66, 575–578.
Husain SR and Puri RK . (2000). Blood, 95, 3506–3513.
Ince TA and Scotto KW . (1995). J. Biol. Chem., 270, 30249–30252.
Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Ellis J and Bonnefoy JY . (1997). J. Biol. Chem., 272, 15613–15619.
Kambayashi T, Jacob CO and Strassmann G . (1996). Cell Immunol., 171, 153–158.
Kawakami K, Taguchi J, Murata T and Puri RK . (2001). Blood, 97, 2673–2679.
Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K and Sugamura K . (1993). Science, 262, 1874–1877.
Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H and Kohler G . (1993). Nature, 362, 245–248.
Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Pontes JE, Leland P, Pastan I, Debinski W and Puri RK . (1997). J. Urol., 158, 948–953.
McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurawski G, Murray R, Grencis R and McKenzie AN . (1998). Immunity, 9, 423–432.
Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vita N and Ferrara P . (1997). FEBS Lett., 401, 163–166.
Murata T, Obiri NI, Debinski W and Puri RK . (1997). Biochem. Biophys. Res. Commun., 238, 90–94.
Na SY, Lee SK, Han SJ, Choi HS, Im SY and Lee JW . (1998). J. Biol. Chem., 273, 10831–10834.
Ogata H, Ford D, Kouttab N, King TC, Vita N, Minty A, Stoeckler J, Morgan D, Girasole C, Morgan JW and Maizel AL . (1998). J. Biol. Chem., 273, 9864–9871.
Pesu M, Aittomaki S, Takaluoma K, Lagerstedt A and Silvennoinen O . (2002). J. Biol. Chem., 277, 38254–38261.
Rousset F, Garcia E and Banchereau J . (1991). J. Exp. Med., 173, 705–710.
Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE and Leonard WJ . (1993). Science, 262, 1880–1883.
Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK and Collins T . (1999). Mol. Cell. Biol., 19, 6367–6378.
Vanden Berghe W, De Bosscher K, Boone E, Plaisance S and Haegeman G . (1999). J. Biol. Chem., 274, 32091–32098.
van der Velden AW and Thomas AAM . (1999). Int. J. Biochem. Cell Biol., 31, 87–106.
Wery-Zennaro S, Letourneur M, David M, Bertoglio J and Pierre J . (1999). FEBS Lett., 464, 91–96.
Wery-Zennaro S, Zugaza JL, Letourneur M, Bertoglio J and Pierre J . (2000). Oncogene, 19, 1596–1604.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL and Donaldson DD . (1998). Science, 282, 2258–2261.
Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D and Nicola NA . (1997). J. Biol. Chem., 272, 9474–9480.
Acknowledgements
We are grateful to Dr P Ferrara for providing IL-4 and IL-13. This work was supported in part by a fellowship to MD D and grants from Association pour la Recherche sur le Cancer (Grant # 5963).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
David, M., Bertoglio, J. & Pierre, J. Functional characterization of IL-13 receptor α2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene 22, 3386–3394 (2003). https://doi.org/10.1038/sj.onc.1206352
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206352
Keywords
This article is cited by
-
Transcriptional regulation of the IL-13Rα2 gene in human lung fibroblasts
Scientific Reports (2020)
-
Generating diversity in human glucocorticoid signaling through a racially diverse polymorphism in the beta isoform of the glucocorticoid receptor
Laboratory Investigation (2017)
-
IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer
Oncogene (2015)
-
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models
Journal of Translational Medicine (2010)
-
IL-13 receptor isoforms: Breaking through the complexity
Current Allergy and Asthma Reports (2007)